Rocklatan header logo
MENU CLOSE

For the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

ONE
POWERFUL
DROP Starts with Rocklatan®

Rocklatan® is the only product to demonstrate superiority to latanoprost in US Phase 3 trials. In a European trial, a ~9.5 mmHg mean diurnal IOP reduction was achieved.1-4*

*Rocklatan® is approved as “Roclanda®” in Europe.

  • IOP, Superior efficacy

    Powerful efficacy

    Rocklatan® demonstrated an average 37% intraocular pressure (IOP) reduction from baseline1

  • QD dosing

    QHS dosing

    One drop, once-daily dosing relieves treatment burden and may improve adherence and treatment outcomes2,5,6

  • Safe and tolerable

    Comprehensive outflow

    Rocklatan® lowers IOP by increasing outflow through the trabecular and uveoscleral pathways7


Making a difference for more glaucoma patients

People living with glaucoma have a lot to manage. According to one study that included free medicine, guided instruction, and electronic monitoring, nearly half of patients took less than 75% of their prescribed dose. Studies show that increasing the complexity of glaucoma therapy resulted in a significant decrease in compliance.5,8

Empower your patients with more information about the benefits of starting Rocklatan®.


Resources created specifically for eye care providers like you

Become a

Access engaging content, educational resources, and Aerie research for glaucoma care and beyond.

IMPORTANT SAFETY INFORMATION

Contraindications

None.

Warnings and Precautions

Increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes can occur. Iris pigmentation likely to be permanent.

Gradual change to eyelashes may include increased length, thickness, number, and misdirected growth of lashes. Usually reversible upon discontinuation of treatment.

Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). Should generally not be used in patients with active intraocular inflammation.

Macular edema, including cystoid macular edema, has been reported with latanoprost. Use with caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with known risk factors for macular edema.

Use with caution in patients with a history of herpetic keratitis. Avoid use in cases of active herpes simplex keratitis.

Bacterial keratitis has been reported with multiple-dose containers of topical ophthalmic products inadvertently contaminated by patients.

Remove contact lenses prior to administration and reinsert 15 minutes after administration.

Adverse reactions

The most common ocular adverse reactions were conjunctival hyperemia (59%), with 5% of patients discontinuing therapy for this reason, instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.

INDICATIONS AND USAGE

ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of ROCKLATAN® should not exceed once daily. ROCKLATAN® may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

Please click here for full prescribing information for ROCKLATAN® Solution

To report Suspected Adverse Reactions, contact Aerie Pharmaceuticals, Inc. at 1-855-740-1924 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

IMPORTANT SAFETY INFORMATION

Contraindications

None.

Warnings and Precautions

Increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes can occur. Iris pigmentation likely to be permanent.

Gradual change to eyelashes may include increased length, thickness, number, and misdirected growth of lashes. Usually reversible upon discontinuation of treatment.

Use with caution in patients with a history of intraocular inflammation (iritis/uveitis). Should generally not be used in patients with active intraocular inflammation.

Macular edema, including cystoid macular edema, has been reported with latanoprost. Use with caution in aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with known risk factors for macular edema.

Use with caution in patients with a history of herpetic keratitis. Avoid use in cases of active herpes simplex keratitis.

Bacterial keratitis has been reported with multiple-dose containers of topical ophthalmic products inadvertently contaminated by patients.

Remove contact lenses prior to administration and reinsert 15 minutes after administration.

Adverse reactions

The most common ocular adverse reactions were conjunctival hyperemia (59%), with 5% of patients discontinuing therapy for this reason, instillation site pain (20%), corneal verticillata (15%), and conjunctival hemorrhage (11%). Eye pruritus, visual acuity reduced, increased lacrimation, instillation site discomfort, and blurred vision were reported in 5-8% of patients.

INDICATIONS AND USAGE

ROCKLATAN® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of ROCKLATAN® should not exceed once daily. ROCKLATAN® may be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.

Please click here for full prescribing information for ROCKLATAN® Solution

To report Suspected Adverse Reactions, contact Aerie Pharmaceuticals, Inc. at 1-855-740-1924 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

References:

  1. Data on file, Aerie Pharmaceuticals, Inc.
  2. Asrani S, Bacharach J, Holland E, et al. Fixed-dose combination of netarsudil and latanoprost in ocular hypertension and open-angle glaucoma: pooled efficacy/safety analysis of phase 3 MERCURY-1 and -2. Adv Ther. 2020;37(4):1620-1631.
  3. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(4):472-484.
  4. Weinreb RN, Ong T, Sforzolini BS, et al. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738-745.
  5. Robin A, Grover DS. Compliance and adherence in glaucoma management. Indian J Ophthalmol. 2011;59:S93-S96.
  6. Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Prescribing Information. Aerie Pharmaceuticals, Inc., Irvine, Calif. 2020.
  7. Brubaker JW, Teymoorian S, Lewis RA, et al. One year of netarsudil and latanoprost fixed-dose combination for elevated intraocular pressure: phase 3, randomized MERCURY-1 study. Ophthalmol Glaucoma. 2020;3(5):327-338.
  8. Prum B Jr, Rosenberg L, Gedde S, et al. Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines. Ophthalmology. 2016;123(1):P41-P111.
X

You are now leaving rocklatan.com/hcp

Continue

Cancel